Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Investor Presentation (January 2024)
14 slides from Legend Biotech's investor presentation, January 2024
Slide 1: Legend Biotech Corporate Presentation
Legend Biotech Corporate Presentation J A N U A RY 2 0 2 4 1 This presentation is for investor relations purposes only – Not for product promotional purposes
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in th
Slide 3: Legend Biotech Highlights
Legend Biotech Highlights Years 9 Since Inception One of the earliest companies 1,800+ Employees 1 Marketed Product: 8 Pipeline Programs Covering: to engineer CAR-T cells for the CARVYKTI® ▪ Hematologic malignancies BCMA protein ~300 Dedicated to R&D (ciltacabtagene autoleucel; cilta-cel)1,2 ▪ Solid
Slide 4: CARVYKTI Uptake Continues
CARVYKTI® Uptake Continues Continued market penetration, geographic expansion, and population in earlier lines of treatment represent significant growth drivers and opportunity Q3’23 OVER CARVYKTI® Net Product Sales ($MM) YOY GROWTH Q2’23 GROWTH +176% growth vs Q3’22 U.S. 155% 23% 160 EU N/A 300% 14
Slide 5: A New Standard for CAR-T Launches
A New Standard for CAR-T Launches CARVYKTI® - INDUSTRY FIRST SIX QUARTERS L E A D I N G E A R LY L A U N C H OUTPERFORMING HISTORICAL PERFORMANCE CAR-T LAUNCHES WORLDWIDE SALES OF CAR -T THERAPIES, BY QUARTER OF LAUNCH (IN $MM) 400 391 Kymriah Yescarta Tecartus Breyanzi Abecma Carvykti 350 300 Quart
Slide 6: Pioneer and Leader in Cell Therapy
Pioneer and Leader in Cell Therapy 6 This presentation is for investor relations purposes only – Not for product promotional purposes
Slide 7: A Fully Integrated Global Leader in Cell Therapy
A Fully Integrated Global Leader in Cell Therapy MARKET-LEADING MULTIPLE MYELOMA (MM) CAR-T THERAPY • sBLA and Type II variation to support label expansion accepted by U.S. FDA (PDUFA target action date of April 5, 2024) and EMA, respectively • Application supported by first randomized Phase 3 study
Slide 8: Our Differentiated R&D Approach
Our Differentiated R&D Approach Potential best-in-class proprietary technology platforms and end-to-end capability Armoring Antibody Diverse platform strategy for screening for allogeneic solid tumors & engineering treatments Multiple armored CAR-T In-house antibody Diverse allogeneic strategies to
Slide 9: Legend and J&J Global Collaboration
Legend and J&J Global Collaboration Worldwide collaboration and license agreement to develop and commercialize cilta-cel Europe 50/50 United States 50/50 50/50 50/50 Japan 70/30 Greater China Upfront Payment Second Milestone Fourth Milestone Sixth Milestone 9th Milestone Eligible for Potential $25 m
Slide 10: Global Manufacturing Footprint
Global Manufacturing Footprint US Facilities EU Facilities China Facilities Raritan, NJ Ghent, Belgium Nanjing Future Commercial Site for Legend China Clinical Supply Site for US / EU / JP / ROW Launch/ Pipeline Programs & Potential China Commercial Site for CARVYKTI® CARVYKTI® Launch Site for CARVY
Slide 11: Expanding Our Manufacturing Capabilities
Expanding Our Manufacturing Capabilities Bringing cell therapies to market given unique challenges to improve overall supply State-Of-The-Art CARVYKTI® Manufacturing Facilities • Obelisc Facility in Ghent, Belgium received license from the Federal Agency for Medicines and Health Products in Belgium
Slide 12: Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3
Out-licensing Deal with Novartis on CAR-T Therapies Targeting DLL3 • Legend announced on Nov 13, 2023 an exclusive, global license agreement with Novartis to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer. • Legend announced on
Slide 13: Our Pipeline
Our Pipeline Global US China PRECLINICAL PHASE 1 PHASE 2 PHASE 3 SCLC‡§ RRMM (BCMA)* NSCLC (DLL3) RRMM (BCMA) HCC† RRMM (BCMA)* 1-3 Prior Lines (GPC3) LEGEND-2† (GPC3) CARTIFAN-1 Autologous CARTITUDE-4 Autologous Autologous Autologous Autologous Autologous NCT05680922 NCT03090659 NCT05352542 NCT0375
Slide 14: Outlook: 2024 and Beyond
Outlook: 2024 and Beyond NEAR-TERM GOALS LONG-TERM GROWTH STRATEGY → Continue to increase manufacturing capacity and → Move CARVYKTI® to earlier lines of therapy; increase efficiency penetration in the US and expand into global markets → Begin manufacturing from Ghent facilities → Focus on unmet med
Legend Biotech — Investor Presentation (January 2024) on 6ix